retatrutide dosing phase 2 trial isn't a GLP-1. It's not a dual agonist. It's a triple hormone receptor agonist — activating GIP, GLP-1, and glucagon simultaneously. Three receptors. Three mechanisms. One protocol. Swipe to see what dosing cagrilintide with retatrutide dosage

You are not obligated to explain your medication to anyone

Learn more about the experts behind our content on our Health Expert Team page.

By directly acting on appetite circuits in the brain, GLP-1 may cause people to experience less hunger

In addition, a head-to-head trial of semaglutide and liraglutide was conducted in the STEP 8 trial, with a mean weight loss of 17.1% in the semaglutide group, which was significantly more effective than liraglutide (mean weight loss of 6.6%)

A 2022 randomized trial of exenatide did not meet its primary endpoint for reducing heavy drinking days in the overall population, though exploratory analyses suggested potential benefits in participants with obesity

Chromium plays a more modest role